Nanology Labs is an IND-stage pharmaceutical company, developing next generation disruptive cancer therapeutics. Nanology Labs' drug delivery platform technology enables active and targeted delivery of therapeutic compounds to various solid tumor tissues. Nanology Labs' lead candidate, T-MX, is a first-in-class nanoparticle agent which can turn cold tumors hot via overcoming hypoxia in solid tumors.